EQT Life Sciences, a division of Swedish PE and VC firm EQT, closed its debut LSP Dementia Fund at its hard cap of €260M ($281.8M).
The fund will invest in 10 to 15 startups working on therapies to cure dementia and neurodegenerative disorders.
The firm's initial target for the fund was €100M ($108.4M), which it had to raise to accommodate limited partners such as the Alzheimer's Association and European Investment Fund.
- EQT already invested capital from the fund into cardiovascular and Alzheimer's therapeutics biotech NewAmsterdam Pharma, Parkinson's therapeutics maker Muna Therapeutics, frontotemporal dementia-focused biotech AviadoBio, and smart care solutions provider Nobi.
- Parent group EQT has €113B ($122.46B) worth of assets under management (AUM).
